Background: Nasopharyngeal carcinoma (NPC) is the most common head and neck cancer in southern China. Induction chemotherapy and concurrent chemo-radiation are major treatment methods for advanced NPC patients. However, patients will develop resistant phenotype during treatment, leading to treatment failure and cancer recurrence. Nevertheless, how NPC acquires chemoresistance remains largely unknown. Nerve growth factor receptor (NGFR) is a neurotrophin receptor and expresses on the plasma membrane. We found that NGFR expression was up-regulated upon cisplatin treatment, which promotes us to investigate the regulatory role of NGFR in mediating cisplatin resistance in NPC. Methods: Real-time PCR, western blot, and immunocytochemistry staining were used to determine the expression level of NGFR in response to cisplatin treatment. In vivo mouse xenograft model was further used to validate the inducing effect in vitro. NGFRspecific shRNA was used to knockdown the expression of NGFR. In vitro toxicity test was performed to test the sensitivity of cells to cisplatin. Results: Cisplatin treatment induced the expression of NGFR in NPC cells. Cisplatinresistant cells were developed by chronic cisplatin treatment. NGFR was significantly up-regulated in cisplatin-resistant cells. In mouse xenograft model, cisplatin treatment also promoted NGFR expression, which further confirmed the inducing effect in vitro. Knockdown of the expression of NGFR could significantly sensitize cisplatin-resistant NPC cells to cisplatin. Conclusion: Our results demonstrated that inducible NGFR expression mediated acquired resistance to cisplatin in NPC. Targeting NGFR might be clinically useful for sensitizing NPC to chemotherapy. Further studies on the therapeutic role of NGFR monoclonal antibody in modulating chemosensitivity are warranted for the development of NGFR as molecular target for NPC treatment. Background: Oral tongue squamous cell carcinoma (OTSCC) is a common form of head and neck cancer. According to the data retrieved from Hong Kong Cancer Registry, there is a 48% increase in oral tongue cancer in our locality during the 10-year period (2001 -2010) . We know that oral cancer has a remarkable increase in the intracellular reactive oxygen species (ROS) content. The oncogenic functions of ROS is well-documented. However, results from many trials had indicated that targeting cancer ROS as a mean for cancer treatment is not feasible. This is because high amount of antioxidant must be used to be effective. The effective dose is not tolerated by human body. In view of the crucial role of ROS, we attempted to identify the key ROS generating enzyme in oral cancer and test the feasibility of target treatment.
Methods: Gene knock-down was performed with the use of shRNA-containing lentivector. In vitro proliferation assays and mouse xenograft models were used to validate the tumorigenic functions. QPCR and luciferase assays were employed to validate the downstream gene target.
Results: Head and neck cancer has a differential upreglation of NADPH oxidase 5 (NOX5). NOX5 can generate superoxides without depending on any subunits. Thus, increasing NOX5 expression will have a direct impact on overall ROS generation in OTSCC. Knocking down NOX5 expression in OTSCC could lead to a remarkable reduce in the xenograft size. These data indicated that NOX5 is an important tumor gene in OTSCC with high potency in promoting OTSCC progression. Mechanistically, we showed that NOX5 is responsible for inducing hypoxia-inducible factor-1 (HIF-1). Also, we demonstrated that superoxide has a strong inducing effect on HIF-1 expression in OTSCC. Thus, the high expression of NOX5 might provide survival advantage to OTSCC at low oxygenation tumor microenvironment.
Conclusions
Our result provide a rationale for targeting NOX5 in OTSCC treatment.
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Background: Cancer stem cells is a small population within the tumor bulks contributing to radiotherapy and chemotherapy resistance. CD271 is reported to be a cancer stem cell markers for head and neck squamous cell carcinoma. The CD271 high population in oral and hypopharyngeal cancer is associated with treatment resistance and poor survival. We tried to explore whether CD271 is a functional cancer stem cell marker for Nasopharyngeal carcinoma (NPC). Methods: CD271 high and low subpopulation in NPC cell lines (HONE1) is sorted by using fluorescence-activated cell sorting (FACS). Genes expression in CD271 high faction will be examined and compared with the CD271 low counterpart using real-time quantitative PCR and immunostaining. Proliferation propensity of CD271 high and CD271 low cells will be examined using real-time monitoring xCELLigence system. Clone formation assay will be performed on parental and sorted cells. We also investigated the tumorigenic capacity of CD271 high population by monitoring tumor formation in nude mice.
Results: FACS analysis showing that cisplatin-resistant NPC had higher proportion of CD271 cells. The percentage of cells with high CD271 expression was 5.0% in parental HONE1 and 36.8% in cisplatin-resistant HONE1 cells respectively. Parental HONE1 cells with high CD271 expression counterpart exhibited higher expression level of pluripotency transcription factors (OCT4, SOX2, NANOG). CD271 high subpopulation of NPC cells also illustrated higher proliferation propensity. In colony formation assay, CD271 high population HONE1 cells showed higher colonies comparing with CD271 low counterpart.
Conclusions: CD271 expression is associated with the enhanced stemness phenotype in NPC with high tumorigenicity. The knowledge may be useful for further development of target therapeutic regime to eradicate the NPC stem cell population.
P2 À 004 Autophagy inhibition improves CD47-blocking immunotherapy in laryngeal squamous cell carcinoma Results: We demonstrated that blocking CD47-SIRPa by SIRPa-Fc could significantly induce cytotoxicity and phagocytosis of LSCC cells. Meanwhile, we found that autophagy was activated by SIRPa-Fc, inducing the activity of LC3 which was converted from LC3-I to LC3-II, while Akt/mTOR signaling pathway was involved in autophagic process. Furthermore, inhibiting SIRPa-Fc-induced autophagy by pharmacological inhibitors or small interfering RNA significantly enhanced SIRPa-Fc-triggered macrophage phagocytosis and cytotoxicity, revealing autophagy played a cytoprotective role in CD47-targeted therapy of LSCC. Moreover, xenograft experiment showed that combination of autophagy inhibitor potentiated the anti-tumor efficacy of SIRPa-Fc, with recruitment of macrophages and apoptosis of tumor cells. Conclusion: These findings demonstrated that CD47-blocking therapies alone and in combination with autophagy inhibitor could potently kill LSCC cells, highlighting potential therapeutic strategies for cancer immunotherapy. 
